PreludeDx

APPs: Are you looking for tools and strategies to help your #DCIS patients with their treatment decisions? Deborah Christensen and Leona Hamrick, DHSc, PA-C are hosting an educational webinar designed specifically for the Advanced Practice Provider. We’ll cover: ·     Effective strategies to address patient concerns and anxiety ·     How to navigate complex DCIS treatment options ·     How to use #DCISionRT to make informed decisions about radiation therapy Register for our webinar on April 9 at 4 p.m. ET.  https://bit.ly/4hQbrFn

Research shows that #DCISionRT helps predict who benefits from radiation therapy after breast-conserving surgery. This test has the potential to reduce both the overtreatment and undertreatment of #DCIS patients. Want to learn more? Come by booth #128 and see us at #SSO2025! #DCIS #breastcancer PreludeDx

When Alexia Vernon was diagnosed with #DCIS, she was overwhelmed by the stories of women facing aggressive intervention. She yearned for a middle path. Her oncological surgeon, Janie Grumley, MD at Providence’s Margie Petersen Breast Center, sent her pathology from an excisional biopsy to PreludeDx. Alexia’s #DCISionRT score showed she had only a 3-5% chance of DCIS or invasive breast cancer recurrence over 10 years with breast-conserving surgery alone. This meant no radiation, no endocrine therapy and no mastectomy. “The results saved me from what could have been over-treatment,” says Alexia. https://bit.ly/4iHxZZX

“As a provider, #DCISionRT test results are incredibly valuable because they give precise, individualized information about a patient’s risk and the potential benefit of specific treatments,” says Dr. Princess Williams of Birmingham Breast Care. By providing personalized results for #DCIS recurrence and invasive cancer recurrence, the #DCISionRT test empowers patients with the data they need to make confident decisions about their care. Read more in our latest blog: https://bit.ly/3FDTZXq

Leona Hamrick, DHSc, PA-C, our VP of Global Medical Affairs, has joined the Tigerlily Foundation Board of Directors! Her personal experience with breast cancer has fueled her passion for helping women gain access to essential resources, support and community during their cancer journeys. We’re proud to see Leona contribute to TigerLily’s vision of ending disparities and improving outcomes for young women and women of color.  Please join us in congratulating Leona on this new and impactful leadership role!

Day 2 of Miami Breast Conference! See you there!

We’re excited to exhibit at #MBCC25 (March 6-9). With #DCIS as a major focus of the conference, we’re looking forward to discussions about how #DCISionRT plays an important role in helping clinicians and patients make more confident treatment decisions. DCISionRT is the only risk assessment test for patients with DCIS that predicts radiation therapy benefit. Are you attending? Stop by table T6 to meet our scientific leadership team. We'd love to connect!

Recently, we welcomed Vincent Reid, MD, FACS Chairman of Surgery & Medical Director, Hall Perrine Cancer Center, Mercy Medical Center to our National Sales Meeting. Key takeaways: ·     Surgeons must collaborate with radiation and medical oncologists as well as nurse navigators to de-escalate #DCIS overtreatment. ·     “Run #DCISionRT up front on the core needle biopsy because it impacts treatment decisions.” ·     “Nothing says DO or DON’T with DCISionRT— it’s just helpful information.” Thank you, Dr. Reid, for championing personalized breast cancer care! #breastcancerawareness

We’re proud to announce our partnership with Hannah Storm, award-winning broadcast journalist, director & producer. In this video, she talks to Dan Forche about how #DCISionRT helped her choose a treatment plan that was right for her — without radiation. “I love your company’s commitment to women — how you want every woman to have access to this test; to let them know what their choices are; and to help them understand their biology,” Storm says. “The beauty of #DCISionRT is that it looks at you as an individual.” Follow PreludeDx to learn more or go to www.preludedx.com

According to the most recent report from the American Cancer Society , women under 50 are 82% more likely to be diagnosed with invasive cancer than men of a similar age. To compare, in 2002, women under 50 were 51% more likely to be diagnosed with cancer than men. Driving these numbers is an increase in invasive breast cancer https://bit.ly/3EdXTFL, the report says, which has gone up 1% each year from 2012 to 2021. Beyond the catchy headlines, numbers like these can inspire action and change. If you are due for a cancer screening, like a mammogram or a colonoscopy, could you take some time to schedule that today? #BCSM #breastcancer #breastcancerawareness #DCIS